Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Doxorubicin in stage II–III, intermediate-risk Wilms’ tumour

In The Lancet, Kathy Pritchard-Jones and colleagues1 from the International Society of Paediatric Oncology (SIOP) report results from their Wilms’ tumour 2001 randomised, controlled, non-inferiority study. They recruited 583 children aged 6 months to 18 years with stage II–III, histological intermediate-risk Wilms’ tumour who had received 4 weeks of preoperative chemotherapy with vincristine and actinomycin D. They randomly assigned the children (1:1) by a minimisation technique to receive either postnephrectomy combination chemotherapy with vincristine and actinomycin D alone—the experimental treatment—or these two drugs plus doxorubicin (a cardiotoxic chemotherapeutic drug),2–4 the standard treatment.

email